Business · Markets · 2 hrs ago
Australian healthcare shares rise after US Democrats’ midterm gains
Australian healthcare shares rose 2.75% after US midterm results pointed to Democratic gains in Congress.
The move was stronger than the broader Australian market, which rose 1.7%.
Investors expect Democrats to favour public health funding and broader insurance coverage, including restoring Affordable Care Act subsidies and resisting proposed Medicaid cuts.
More coverage could improve hospital finances and increase prescription volumes, while drug pricing and research funding remain uncertain.
Neuren Pharmaceuticals raised its earnings guidance on sales of its Rett syndrome drug and its shares climbed 16%.
Other Australian health stocks also gained, including ProMedicus, Cochlear, Telix and CSL.
The policy effects are still unclear, as Congress may also debate drug prices and domestic manufacturing.
The S&P/ASX 200 healthcare sector rose 2.75% after US Democrats made gains in the midterm elections.
The sector outperformed the broader Australian market, which rose 1.7%.
Investors saw the Democratic gains as potentially positive for healthcare funding and medical research.
Neuren Pharmaceuticals shares rose 16% after the company upgraded its earnings guidance.
Other Australian healthcare stocks, including ProMedicus, Cochlear, Telix Pharmaceuticals and CSL, also gained.
- Who
- Australian healthcare companies and investors.
- What
- ASX healthcare shares rose after Democrats made gains in the US midterm elections.
- When
- November 5, 2026.
- Where
- Australia, following US midterm elections.
- Why
- Investors expected Democratic gains could support public health funding and medical research. The article says the implications for healthcare policy remain uncertain.
This story does not have two clearly opposing sides.
Americans voted in the US midterm elections.
The Dow rose 3% and the Nasdaq biotech index gained 2.7%.
The S&P/ASX 200 healthcare sector rose 2.75%, while the broader market gained 1.7%.
- ASX healthcare sector
- Up 2.75%
- Broader Australian market
- Up 1.7%
- Neuren Pharmaceuticals
- Shares rose 16%; company upgraded earnings guidance
- ProMedicus
- Shares rose almost 8%
- Cochlear
- Shares rose 5%
- CSL
- Shares rose 1.4%
What people are saying
In many ways this is a victory for the ‘swamp’ and they return to business as usual
Coverage expansion is also likely to improve hospital finances and prescription volumes.